CEL-SCI Corporation (NYSE MKT: CVM) announced today that during its annual Shareholder’s Meeting on June 12, 2017, a 1-for-25 reverse split was authorized for its outstanding shares of common stock. CEL-SCI expects the split to be …
* Cel-Sci Corp - a 1-for-25 reverse split was authorized for its outstanding shares of common stock Source text for Eikon: Further company coverage: Our Standards:The Thomson Reuters Trust Principles.
Reuters10mon
liso-cel (formerly JCAR017), and it owns nearly 10% of Juno Therapeutics' stock, yet that may not be enough to satisfy Celgene's desire to become a gene-therapy leader. According to The Wall Street Journal, Celgene is thinking about …
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announced today that during its annual Shareholder’s Meeting on June 12, 2017, a 1-for-25 reverse split was authorized for its outstanding shares of common …
Cel-Sci - entered definitive agreement with one institutional investor for offering of shares of stock with proceeds of about $1.51 million in direct offering * Cel-Sci corp- intends to use net proceeds from offering for phase 3 clinical study and …
Reuters11mon
CEL-SCI to issue about 1.8 million registered shares of common stock at a purchase price of $2.00 per share Source text for Eikon: Further company coverage: Our Standards:The Thomson Reuters Trust Principles.
* Cel-Sci Corp - a 1-for-25 reverse split was authorized for its outstanding shares of common stock Source text for Eikon: Further company coverage: